Traxlink P Tablet contains Proanthocyanidin 75 mg and Tranexamic Acid 250 mg, a synergistic formulation for hemostatic support and vascular protection. Proanthocyanidins strengthen capillary walls and improve microcirculation, while Tranexamic Acid acts as an antifibrinolytic, preventing excessive blood loss by stabilizing blood clots.
Clinically, Traxlink P Tablet is indicated for menorrhagia, postoperative bleeding, and other conditions associated with abnormal or excessive bleeding. The combination works to reduce bleeding duration, minimize clot breakdown, and improve vascular resilience, supporting faster recovery and patient comfort.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospitals, gynecology clinics, hematology centers, and specialty pharmacies. Its oral formulation allows for easy administration and enhanced patient adherence.
Traxlink P Tablet also contributes to overall hemostatic stability, prevention of hemorrhagic complications, and improved quality of life for patients prone to bleeding disorders. Its evidence-based composition makes it a trusted, safe, and effective option for managing hemostasis in routine clinical practice.